In the Expert Opinion on Drug Safety 2011; 10: 633-643 for the article ‘Safety of rasagiline for the treatment of Parkinson's disease,’ the authors have noticed some errors since publication.
In Section 2 ‘Pharmacokinetics, pharmacodynamics and clinical pharmacology of rasagiline’ in the sentence beginning ‘Rasagiline (N-propargyl-1(R)-aminoindan)…,’ the words ‘orders of magnitude’ have been omitted when referring to the comparison of the [R] and [S] isomer MAO inhibition and the sentence should have read as follows:
‘Rasagiline (N-propargyl-1(R)-aminoindan) is a propargylamine and, as the R-enantiomer, exhibits in vitro four orders of magnitude more potency than the S-enantiomer in terms of MAO inhibition [15].’
The authors and publishers apologize for these errors.